

Media Contact: John Wilkie Phone: 262.524.1402, extension 111 jwilkie@invivocorp.com		Invivo Corporation N27 W23676 Paul Rd. Pewaukee, WI 53072
--	--	--

FOR IMMEDIATE RELEASE

Invivo Introduces NeuroQuant on DynaSuite Neuro at RSNA 2010

Pewaukee, Wisc., November 29, 2010 – Invivo, a worldwide leader in the development and manufacturer of MRI Clinical Solutions, announces effective today, an agreement with CorTechs Labs, to be the key distributor for the NeuroQuant product in the U.S. marketplace. NeuroQuant, will augment the DynaSuite Neuro Solution from Invivo by providing enhanced diagnostic capabilities to health care practitioners that may help in the assessment of patients with Alzheimer’s, Epilepsy and other neurological disorders. For Alzheimer’s, clinicians will have quantitative measures of brain atrophy to consider along with other clinical and biomarker data when making a diagnosis or when monitoring disease progression. NeuroQuant is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images.

DynaSuite Neuro by Invivo provides a platform to help transition advanced neuro applications and functional MRI from the research environment to the day-to-day clinical practice. It offers the workflow and productivity which allow radiologists to perform advanced neuro analysis. By incorporating the NeuroQuant application, neurologists, radiologists, and clinical researchers can now use DynaSuite Neuro to quantify the volume of the hippocampus and other neuro structures.

NeuroQuant takes a high-resolution 3D T1-weighted, sagittal, non-contrast-enhanced MRI scans and automatically processes the large amount of data for easy physician review. It returns a new full-volume spatially corrected and anatomically labeled dataset with two printable patient reports containing the absolute and relative volumes of the hippocampus, temporal horn, and other structures. The new, integrated diagnostic solution comes at an increasingly important time for the early detection of Alzheimer’s disease and other disorders.

Alzheimer’s disease is the seventh-leading cause of death in the United States. An estimated 5.3 million Americans of all ages have Alzheimer’s disease. This figure includes 5.1 million people aged 65 and older and 200,000 individuals under age 65 who have younger-onset Alzheimer’s. The Alzheimer’s Association estimates that there are 500,000 Americans younger than 65 with Alzheimer’s and other dementias. ⁽¹⁾

-more-

“We are excited about the NeuroQuant partnership and expanding the capabilities of DynaSuite Neuro. It is consistent with our strategy to extend our leadership position in advanced Neuro Solutions.” said Michael Kapp, product manager for Neuro Solutions at Invivo. “Invivo is delighted to offer this product by CorTechs Labs as it complements our existing portfolio.”

Michael Smith, president of CorTechs Labs said “It was extremely important for to us to identify a partner that shares the same goals as our company and has the ability to provide customers with a first class service, support and distribution network. Invivo clearly fits the criteria we identified to promote our innovative solution for diagnostic imaging facilities.”

The scientists, engineers, business professionals, and clinical specialists at CorTechs Labs, Inc. are dedicated to creating advanced medical image analysis solutions for measuring the structure and function of the human brain. CorTechs' research and development efforts are supported in part by competitively awarded grants from the US National Institutes of Health. NeuroQuant has been developed and validated with SBIR funding from the National Institute of Aging. CorTechs Labs is located in La Jolla, Calif.

Invivo has an over 20-year history as the pioneer of progressive MRI coils, advanced clinical visualization systems, and MRI-compatible interventional devices. The Company prides itself on successfully developing and manufacturing high-value-added medical products to enhance MR image quality, improve physicians’ diagnostic confidence and patients’ health care experience. For more information please visit www.invivocorp.com.

¹ Alzheimer’s Association, Early-Onset Dementia: A National Challenge, A Future Crisis. (Washington, D.C.: Alzheimer’s Association, June 2006). Available at www.alz.org

NeuroQuant is a registered trademark of CorTechs Labs, Inc.

- End -